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Abstract Germline mutations in the two breast cancer
susceptibility genes, BRCA1 and BRCA2 account for a
significant portion of hereditary breast/ovarian cancer. De
novo mutations such as multiple exon deletion are rarely
occurred in BRCA1 and BRCA2. During our mutation
screening for BRCA1/2 genes to Chinese women with risk
factors for hereditary breast/ovarian cancer, we identified a
novel germline mutation, consisting of a deletion from
exons 1 to 12 in BRCA1 gene, in a patient diagnosed with
early onset triple negative breast cancer with no family
history of cancer. None of her parents carried the mutation
and molecular analysis showed that this novel de novo
germline mutation resulted in down-regulation of BRCA1
gene expression.
Keywords Breast cancer  BRCA1 gene 
De novo mutation  Early onset
Abbreviations
DCIS Ductal carcinoma in-situ
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ER Estrogen receptor
BIC Breast cancer information core
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Introduction
Breast cancer is the most frequently occurring malignancy
in women. Germline mutations in the two breast cancer
susceptibility genes, BRCA1 and BRCA2 account for a
significant portion of hereditary breast/ovarian cancer [1].
BRCA mutations are distributed over all exons and there-
fore genetic testing for these BRCA1/2 genes require a
mutation screening method of the entire coding regions of
the genes. In our laboratory in Hong Kong, we currently
offer mutation screening for BRCA1/2 genes to Chinese
women with breast or ovarian cancer at age 50 years and
younger, or with a family history of BRCA related cancers
such as breast, ovarian, colon, and prostate, using direct
full gene sequencing. However, in many countries, breast
cancer patients without family history are generally not
tested. For example, in the United Kingdom it is estimated
that up to 6% of the BRCA1 and BRCA2 mutation cases are
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missed because they lack a family history of relevant
cancers. Lack of a family history may relate to small family
size, non-penetrance, premature death, loss of contact with
family members, and inadequate information [2]. Alterna-
tively, lack of family history can also be explained by new
germline mutations found in the probands but not in any of
their family members. Such de novo mutations have been
reported in diseases such as hemophilia A [3] and thalas-
saemia [4]. De novo mutations are very rare among BRCA
genes [5–8]. Moreover, most of the reported disease-
associated mutations in BRCA1 and BRCA2 result in
frame shift, nonsense, insertions, deletions, or splice site
alterations, which lead to formation of a truncated BRCA
protein. However, large genomic rearrangements in
BRCA1 and BRCA2 are rarely seen, and a similar BRCA1
deletion (from exon 1 to 13) has been reported in Finland
[9]. Hereby, we describe a de novo mutation in which
multiple exons were deleted from BRCA1 in a Chinese
breast cancer patient. Furthermore, we demonstrate that
significant reduction in BRCA1 RNA levels in the proband
by qRT-PCR assays, suggesting the absence of truncated
BRCA1 RNA products. The results from this case report
illustrate the importance of gene rearrangement testing in
addition to full gene sequencing in detecting BRCA1 and
BRCA2 mutations in breast or ovarian cancer patients, even
in the absence of a strong family history.
Materials and methods
Patient history and paternity confirmation
We report a 33-year old Chinese woman who at age 30 was
diagnosed with grade 2 invasive ductal NOS breast carci-
noma and confirmed to be a triple negative cancer (ER, PR
and Her2/Neu negative). No family history of cancers was
reported. Due to a complicated family history (Fig. 1),
familial relationship of this group was confirmed by pater-
nity test (IdentifilerTM System, 15?1 markers, Applied
Biosystems Foster City, CA). The results of paternity test
were shown in Supplementary Tables 1–3.
Conventional DNA sequencing
BRCA1 and BRCA2 mutation detection was performed on
genomic DNA extracted from peripheral blood samples or
paraffin embedded tissue. DNA was extracted using QIA-
GEN DNA Mini Kit (Qiagen, Hilden, Germany) according
to manufacturer instructions. Mutation analysis was per-
formed by direct DNA sequencing of all coding exons of
BRCA1 and BRCA2 and partial flanking intronic sequences
as described previously [10]. PCR conditions and primer
sequences are available upon request. Bi-directional
sequencing was performed using BigDye Terminator v3.1
Cycle Sequencing Kit and analyzed on an ABI 3130xl
genetic analyzer (Applied Biosystems). Sequencing results
were compared with the reference DNA sequences
(NM_007294.3) using Variant Reporter software (Applied
Biosystems) and then reviewed manually. Computational
analysis for potential cryptic splice site mutation was per-
formed using splice site prediction programs such as
NNSPLICE and ESEF finder when sequence changes were
identified. All mutation and sequence variants are named
according to the recommendations for the description of
sequence variants of Human Genome Variation Society
(HGVS).
Multiplex ligation-dependent probe amplification
Multiplex Ligation-dependent Probe Amplification (MLPA)
was performed to determine the presence of large genomic
rearrangements in the DNA of the proband. The MLPA kit
P002 and P045 (MRC-Holland, Amsterdam, Netherlands)
was used for BRCA1 and BRCA2 gene copy number deter-
mination respectively [10–14]. DNA samples were pro-
cessed according to manufacturer protocol. Each MLPA
analysis was carried out with 5 normal control samples.
Amplification products were electrophoresed on an ABI
3130xl genetic analyzer and interpreted using GeneMapper
software (Applied Biosystems). Results were exported to the
Coffalyser program (MRC-Holland) for further analysis.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from blood samples of patients
and controls. 0.5 lg of total RNA was reversely transcribed
into cDNA with High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems). Real-time qPCR was
Fig. 1 Family pedigree of proband family. The proband (III-4) is
indicated by an arrow
234 A. Kwong et al.
123
performed using QuantiTect SYBR Green PCR Kit (Qia-
gen) in ABI PRISM 7900 HT system (Applied Biosys-
tems). All primer sequences are listed in Supplementary
Table 4. The expression levels were normalized to house-
keeping genes, Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). DCt was calculated by subtracting the Ct
values of GAPDH genes from the Ct values of BRCA1.
DDCt was then calculated by subtracting DCt of the pro-
band from DCt of non-proband. Fold change of gene was
calculated by the equation 2-DDCt.
Statistical analysis
Statistical significance was determined by Mann–Whitney
test. All P-values are two-sided and \0.05 was considered
statistically significant by GraphPad PRISM 4 software
(GraphPad Software, La Jolla, CA).
Results
Based on the lower incidence of breast cancer in Asia
cohorts [10, 15], we offer BRCA1/2 genetic testing for
clinically high risk female patients; high risk being defined
as having (1) at least one first- or second-degree relative
with breast and/or ovarian cancer, regardless of age; (2) a
diagnosis made when less than 51 years of age; (3) bilat-
eral breast cancer; (4) triple negative or medullary type
pathology; (5) at least one relative with cancers other than
breast and ovarian cancer that are known to be related to
BRCA mutations; or (6) ovarian cancer with a family his-
tory of breast cancer. Between March 2007 to November
2010, a total of 530 Chinese female patients with breast
and/or ovarian cancer were screened by BRCA1/2 genetic
testing. Genomic DNA extracted from peripheral blood
samples were sent to Hong Kong Hereditary Breast Cancer
Family Registry. BRCA1 and BRCA2 mutation screening
was performed by direct sequencing of all exons in BRCA1
and BRCA2 and partial flanking intronic sequences [10, 16,
17]. Our sequencing results identified 68 (12.8%) delete-
rious BRCA gene mutations. A total of 29 (29/530, 5.5%)
were in BRCA1 and 39 (39/530, 7.4%) in BRCA2. During
this period of BRCA1/2 genetic testing, this 33 year old
Chinese patient was also eligible for such genetic testing.
Based on our sequencing results, nucleotide changes in
both BRCA1 and BRCA2 from the proband were listed in
Supplementary Table 5. In addition to DNA sequencing,
MLPA was used to determine if large genomic rearrange-
ments existed for the proband. As a result, this is the only
case so far we identified a large deletion of exon 1 to exon
12 of BRCA1 by MLPA (Fig. 2). Analysis of BRCA2 did
not show any signs of large deletions or duplications.
MLPA was also conducted on 5 family members of the
proband: mother, father, biological sister, maternal aunt
and half sister (daughter of proband’s maternal aunt and the
same biological father) (Fig. 1). No signs of this or other
large deletions in either BRCA1 or BRCA2 in any of the
family members were detected, suggesting that there are no
carriers of the reported large deletion in the family.
Therefore the reported large deletion appears to be a de
novo mutation.
To investigate whether the defective BRCA1 allele in the
proband could produce protein product, we first attempted
to perform RT-PCR to detect whether the presence of
Fig. 2 MLPA probes signals
and result of the analysis.
Coffalyser Sample Plate
Generator (S.P.G.) was used to
automatically create sample
plate files for MLPA analysis.
Results shown that probe
signals from exon 1 to 12 were
significantly decreased
indicating the presence of
deletion across those exons
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truncated BRCA1 RNA products for protein truncation
testing, but our attempts were not successful. Therefore, we
postulate such truncated RNA product is not expressed in
the proband. To prove our postulation that such truncated
BRCA1 RNA product do not exist, one of the indirect ways
is to compare BRCA1 RNA levels between proband and
non-proband. If the amount of BRCA1 RNA levels
expressed from both wild-type and defective alleles in the
proband are significantly lower than control, it would be
reasonable to conclude the absence of the truncated RNA
products from the defective allele. Thus, we need to design
four sets of qRT-PCR primer pairs in which two sets of
primer pairs targeting region within the putative deletion
(PCR amplicons cover exon 2–7 and exon 10–11, respec-
tively). Thus, these qPCR assays only amplify BRCA1 RNA
from wild-type allele). The other 2 set of primer pairs target
the region outside the putative deletion (PCR amplicon
cover exon 17–20 and exon 23–24, respectively). Therefore
these qPCR assays amplify BRCA1 RNA from both wild-
type and deleted alleles. As a result, BRCA1 RNA levels
from each amplicon region (within or outside deleted
regions) were compared between proband and non-proband
(non-BRCA mutation carriers) including family members
(n = 5) and normal controls (n = 18). Our results indicated
that for RT-PCR targeting the deleted region (either E2-7
or E10-11), BRCA1 RNA levels in the proband were
significantly lower than that in non-probands (All
P-values \ 0.05, Mann–Whitney test; Fig. 3a). Similarly,
for RT-PCR targeting outside the deleted region (either
E17-20 or E23-24), BRCA1 RNA levels in the proband
were also significantly lower than that in non-probands (All
P-values \ 0.05, Mann–Whitney test; Fig. 3b). Combining
all this data, it demonstrates that overall BRCA1 RNA
expression levels in the proband (defective allele carrier)
was significantly lower than that in controls, suggesting the
existence of truncated BRCA1 RNA products is unlikely.
Discussion
In this study, we report a novel de novo BRCA1 mutation
encompassing deletion from exons 1 to 12 in a Chinese
breast cancer patient of early onset with no family history.
Such de novo mutation is extremely rare and has not been
reported so far. As the large deletion was identified only by
MLPA, it underlines the importance of pursuing gene
rearrangement testing if full gene sequencing fails to detect
mutations or deletions in BRCA1/2 genes. Furthermore,
significant reduction in BRCA1 RNA expression levels in
the proband is confirmed by RT-PCR assays targeting both
PCR products within and outside deleted region, suggesting
no truncated BRCA1 RNA transcript was expressed. Thus,
our unsuccessful attempts to amplify the suspected
truncated product for protein truncation test were expected.
Such deletion results in suppression of BRCA1 protein
production in the defective allele. Unfortunately, the
breakpoint location of the deletion is still being mapped. We
postulate that the deletion breakpoint is located more than
10 kb upstream from the BRCA1 transcriptional start site.
Although most of the identified deleterious mutations in
BRCA1/2 are truncating mutations resulting in a non-
functional protein, large gene rearrangements related to
deletion may not be detected by non-quantitative tech-
niques [18]. The emerging technologies such as the use of
high density probes combined with array comparative
genomic hybridization (aGCH) has identified novel large
genomic deletions [19]. Mutation screening is important in
early onset breast cancer patients even if there is no family
history.
Many factors might lead to the observed mutation in the
studied family. This could be due to sporadic germline
Fig. 3 BRCA1 RNA level comparison between proband and non-
probands (family members and normal controls). Box plots of BRCA1
RNA expression levels a targeting the deleted region b targeting
outside the deleted region of the proband and non-proband (n = 23).
Expression levels (Log10 scale at Y-axis) are normalized to GAPDH.
The lines inside the boxes denote the medians. The boxes mark the
interval between the 25th and 75th percentiles. The whiskers denote
the interval between the 10th and 90th percentiles. Statistically
significant differences were determined using Mann–Whitney tests
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BRCA1 mutations, or the mutation could have been
inherited from an asymptomatic mosaic parent. Consan-
guineous marriage in this family could be another factor.
The rate of consanguineous marriages in Asian countries
such as China, Singapore and Hong Kong was below 10%
[20]. This was lower than Iran in which the rate is around
40% and the first cousin marriages are the most common
type can affect the pattern of genetic disorders in the
population [21]. Another report estimated that 20% of
cases of breast cancer diagnosed in women in Pakistan
aged below 40 years are attributable to first-cousin mar-
riages [22].
In conclusion, we report a novel de novo mutation in the
BRCA1 gene, resulting in breast cancer in a very young
Chinese woman, consisting of a deletion from exon 1 to 12.
Such de novo mutation is extremely rare and to the best of
our knowledge this is the first case reported in Asian
population so far. This patient presents significantly low
expression levels of BRCA1 RNA, indicating the existence
of truncated BRCA1 RNA products is unlikely.
Acknowledgments We sincerely thank to Dr Ellen Li Charitable
Foundation and Kerry Group Kuok Foundation for their support. We
also like to thank Dr Dacita Suen, Dr Catherine Choi and Ms. Wong
Ling for helping in patient recruitment.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity
and penetrance analysis of the BRCA1 and BRCA2 genes in
breast cancer families. The Breast Cancer Linkage Consortium.
Am J Hum Genet 62(3):676–689. doi:S0002-9297(07)63848-8
2. Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D (2009)
Identification of a de novo BRCA1 mutation in a woman with early
onset bilateral breast cancer. Fam Cancer 8(4):479–482. doi:
10.1007/s10689-009-9270-8
3. Antonarakis SE, Kazazian HH, Tuddenham EG (1995) Molecular
etiology of factor VIII deficiency in hemophilia A. Hum Mutat
5(1):1–22. doi:10.1002/humu.1380050102
4. Rojnuckarin P, Settapiboon R, Vanichsetakul P, Sueblinvong T,
Sutcharitchan P (2007) Severe beta(0) thalassemia/hemoglobin E
disease caused by de novo 22-base pair duplication in the paternal
allele of beta globin gene. Am J Hematol 82(7):663–665. doi:
10.1002/ajh.20816
5. Robson M, Scheuer L, Nafa K, Ellis N, Offit K (2002) Unique de
novo mutation of BRCA2 in a woman with early onset breast
cancer. J Med Genet 39(2):126–128
6. Tesoriero A, Andersen C, Southey M et al (1999) De novo
BRCA1 mutation in a patient with breast cancer and an inherited
BRCA2 mutation. Am J Hum Genet 65(2):567–569. doi:10.1086/
302503
7. van der Luijt RB, van Zon PH, Jansen RP, van der Sijs-Bos CJ,
Warlam-Rodenhuis CC, Ausems MG (2001) De novo recurrent
germline mutation of the BRCA2 gene in a patient with early
onset breast cancer. J Med Genet 38(2):102–105
8. Hansen TV, Bisgaard ML, Jonson L et al (2008) Novel de novo
BRCA2 mutation in a patient with a family history of breast
cancer. BMC Med Genet 9:58. doi:10.1186/1471-2350-9-58
9. Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R (2008)
Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes
in Finnish breast and ovarian cancer families. BMC Cancer
8:146. doi:10.1186/1471-2407-8-146
10. Kwong A, Wong LP, Wong HN et al (2009) A BRCA2 founder
mutation and seven novel deleterious BRCA mutations in
southern Chinese women with breast and ovarian cancer. Breast
Cancer Res Treat 117(3):683–686. doi:10.1007/s10549-009-
0385-2
11. Sellner LN, Taylor GR (2004) MLPA and MAPH: new tech-
niques for detection of gene deletions. Hum Mutat 23(5):413–419
12. Hogervorst FB, Nederlof PM, Gille JJ et al (2003) Large genomic
deletions and duplications in the BRCA1 gene identified by a
novel quantitative method. Cancer Res 63(7):1449–1453
13. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens
F, Pals G (2002) Relative quantification of 40 nucleic acid
sequences by multiplex ligation-dependent probe amplification.
Nucleic Acids Res 30(12):e57
14. Bunyan DJ, Eccles DM, Sillibourne J et al (2004) Dosage anal-
ysis of cancer predisposition genes by multiplex ligation-depen-
dent probe amplification. Br J Cancer 91(6):1155–1159
15. Kwong A, Wong CH, Shea C, Suen DT, Choi CL (2010) Choice
of management of southern chinese BRCA mutation carriers.
World J Surg. doi:10.1007/s00268-010-0477-5
16. Kwong A, Wong LP, Chan KY, Ma ES, Khoo US, Ford JM
(2008) Characterization of the pathogenic mechanism of a novel
BRCA2 variant in a Chinese family. Fam Cancer 7(2):125–133.
doi:10.1007/s10689-007-9155-7
17. Kwong A, Ng EK, Law FB et al (2010) High-resolution melting
analysis for rapid screening of BRCA2 founder mutations in
Southern Chinese breast cancer patients. Breast Cancer Res Treat.
doi:10.1007/s10549-010-0882-3
18. Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations
in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of
breast cancer. JAMA 295(12):1379–1388. doi:10.1001/jama.
295.12.1379
19. Staaf J, Torngren T, Rambech E et al (2008) Detection and
precise mapping of germline rearrangements in BRCA1, BRCA2,
MSH2, and MLH1 using zoom-in array comparative genomic
hybridization (aCGH). Hum Mutat 29(4):555–564. doi:10.1002/
humu.20678
20. Bildirici M, Kokdener M, Ersin O (2010) An empirical analysis
of the effects of consanguineous marriages on economic devel-
opment. J Fam Hist 35(4):368–394
21. Saadat M (2007) Consanguineous marriages in Iranian folktales.
Community Genet 10(1):38–40. doi:10.1159/000096280
22. Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA
(2002) Contribution of BRCA1 and BRCA2 mutations to breast
and ovarian cancer in Pakistan. Am J Hum Genet 71(3):595–606.
doi:S0002-9297(07)60339-5
A novel de novo BRCA1 mutation in a Chinese woman 237
123
